<DOC>
	<DOCNO>NCT01206075</DOCNO>
	<brief_summary>Thalassemia consider common genetic disorder worldwide , occur high frequency Mediterranean area , Middle East , Southeast Asia , Pacific Islands . Currently , cure thalassemia bone marrow transplantation relate , compatible donor . Gene transfer , achieve transplantation patient 's blood stem cell genetically-modified corrected gene , could potentially cure thalassemia . The first step develop gene transfer treatment thalassemia develop safe effective method obtain blood stem cell thalassemia patient . Eventually , high number genetically modify cell need infused patient clinical gene transfer effective . The blood stem cell obtain give `` mobilization '' agent patient . This cause stem cell leave bone marrow go blood . The purpose study test safety effectiveness new mobilization agent , Mozobil , cause mobilization blood stem cell patient beta-thalassemia major .</brief_summary>
	<brief_title>Evaluating Safety Effectiveness Mozobil Mobilization Adults With Beta-Thalassemia Major</brief_title>
	<detailed_description>The purpose study optimize blood stem cell mobilization adult beta thalassemia major . We seek method mobilization safe , minimum side effect , yield high number blood stem cell . For successful gene therapy thalassemia , high number genetically modify stem cell need introduce patient . Participants include beta-thalassemia patient fail mobilize sufficiently G-CSF ( previous protocol ) new patient . In study focus safety effectiveness mobilization Mozobil Mozobil plus G-CSF . Following mobilization , blood stem cell recover use leukapheresis , procedure similar blood donation , mobilize white blood cell collect blood patient . During drug administration leukapheresis , patient hospitalize George Papanicolaou Hospital Thessaloniki , Greece . Patients fail mobilize previous protocol receive Mozobil G-CSF hospitalize 5-8 day duration drug administration leukapheresis . They receive G-CSF several day ; Mozobil add last day G-CSF . New patient receive Mozobil hospitalize 2-3 day drug administration leukapheresis . Mozobil administer 240µg/kg , skin . Participants undergo two three leukapheresis procedure row low number blood stem cell recover first ( possibly second ) leukapheresis . Participants discharge hospital day follow last leukapheresis procedure . Weekly follow-up visit occur next month , either G. Papanicolaou Hospital , participant 's local doctor 's office . The total period study participation approximately 5 week . In event Mozobil alone cause mobilization high level blood cell , patient invite repeat protocol three month later , receive Mozobil G-CSF .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Βeta thalassemia major Age &gt; 18 &lt; 50 Karnofsky performance status ³80 % Splenectomized patient patient spleen volume &lt; 800cm3 ( non splenectomized patient receive Mozobil + GCSF ) Compliant regular transfusion regular chelation Liver iron MRI &lt; 280μmol/gr ³1.7msec T2*MRI Heart iron MRI &gt; 2.8 ( SI/SD ) ³9msec T2*MRI Hepatitis B C virus load negative PCR ( polymerase chain reaction ) Left ventricular ejection fraction ( LVEF ) &gt; 45 % echocardiogram Adequate respiratory function DLCO &gt; 50 % Negative pregnancy test , female Ability give inform consent willingness meet expect requirement protocol duration study History thrombosis know thrombophilia Symptomatic viral , bacterial fungal infection within 6 week prior eligibility evaluation Pregnancy lactation HIV positivity History malignancy , local skin cancer Other systematic disease non thalassemiaassociated Splenectomized patient platelet count &gt; 900,000 ( splenectomized patient receive low dose GCSF+ Mozobil ) Additional risk factor thrombosis , include Factor V Leiden ; antiphospholipid antibody less 50 % low normal value follow procoagulants : antithrombin 3 , protein C , protein S .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Beta Thalassemia Major</keyword>
	<keyword>Hematopoietic Stem Cell Mobilization</keyword>
	<keyword>Gene Transfer Techniques</keyword>
</DOC>